Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer. Through these filings, investors can review Rigel’s official disclosures on its commercial portfolio, clinical pipeline and financial condition.
Rigel’s SEC submissions include current reports on Form 8-K that furnish press releases such as quarterly financial results and business updates. For example, recent 8-K filings reference press releases titled “Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update” and “Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update.” These documents outline total revenues, net product sales from TAVALISSE, GAVRETO and REZLIDHIA, contract revenues from collaborations, costs and expenses, net income, and cash, cash equivalents and short-term investments.
Filings also confirm key corporate details, including that Rigel Pharmaceuticals, Inc. is incorporated in Delaware and that its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol RIGL. Investors can use these records to verify listing status, security information and the company’s description as a biotechnology business dedicated to therapies for hematologic disorders and cancer.
On Stock Titan’s SEC filings page, users can follow Rigel’s real-time submissions from the SEC’s EDGAR system, including Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements. AI-powered summaries help explain the key points of lengthy filings, highlighting items such as revenue composition, collaboration-related contract revenues, and updates on clinical programs like the Phase 1b study of R289 in lower-risk myelodysplastic syndrome.
In addition, the platform can surface insider transaction reports on Form 4 when filed, giving users a view into equity awards and other insider activity. By combining original SEC documents with AI-generated insights, this page is intended to make Rigel’s regulatory disclosures more accessible to both individual and professional investors.
Rigel Pharmaceuticals director receives new stock option grant. Director Michael Patrick Miller was awarded a stock option for 12,000 shares of Rigel common stock on February 1, 2026, with an exercise price of $34.86 per share. The option vests in equal monthly installments from February 1, 2026 until the annual meeting at which he is first scheduled to be considered for election by stockholders, conditioned on his continued service on the board.
Rigel Pharmaceuticals director Michael Patrick Miller reported his initial ownership of company securities. He directly holds 187 shares of common stock and a stock option for 625 shares at an exercise price of $16.05 per share, expiring on October 3, 2034.
Of this option, 375 shares are already vested. The remaining 250 option shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, giving a clear schedule for when he gains full option rights.
Rigel Pharmaceuticals, Inc. appointed Michael P. Miller to its board of directors effective February 1, 2026. He will serve in the director class whose term ends at the 2027 annual stockholders’ meeting and will also join the company’s Compensation Committee.
As a non-employee director, Mr. Miller will receive a yearly cash retainer of $50,000, plus an additional annual $10,000 retainer for Compensation Committee service, both pro-rated for partial service periods. He received an initial stock option grant to purchase 12,000 shares of common stock under Rigel’s 2018 Equity Incentive Plan.
After each annual stockholders’ meeting, he will automatically receive an annual option to purchase 3,000 shares of common stock and 2,500 restricted stock units, pro-rated for any year of partial service, so long as he continues to serve as a non-employee director. The company entered into its standard indemnification agreement with him and states that he is independent, has no disclosable related-party transactions, and no family relationships with the company’s directors or executive officers.
Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025. These estimates are based on currently available information and do not include all details needed for a complete picture of the company’s financial condition or operating results for that period.
The company also disclosed that it issued a press release titled “Rigel Provides Business Update and 2026 Outlook,” which is included as Exhibit 99.1. That release contains a broader business update and the company’s outlook for 2026, and is incorporated by reference into this report.
Rigel Pharmaceuticals' EVP & Chief Financial Officer reported option exercises and updated holdings. On 12/22/2025, the officer exercised three employee stock options (code M), acquiring 1,987 shares at
Following these transactions, the officer beneficially owned 64,235 shares of Rigel common stock, which includes 500 shares acquired under the company’s stock purchase plan. The filing also shows remaining employee stock options covering 14,262, 17,153, and 10,832 shares, with expiration dates ranging from 01/23/2029 to 01/26/2033. All share numbers reflect a one-for-ten reverse stock split effective June 27, 2024, and the options vest in equal monthly installments over four years from their respective vesting commencement dates.
Rigel Pharmaceuticals furnished a press release announcing its financial results for the third quarter ended September 30, 2025 and providing a business update. The press release was included as Exhibit 99.1.
The company specified that this information is furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other SEC filings.
Rigel Pharmaceuticals reported strong Q3 2025 results. Total revenue was $69,462 (thousands), driven by net product sales of $64,067 (thousands) and collaboration revenue of $5,395 (thousands). Operating income reached $28,420 (thousands), and net income was $27,900 (thousands), or diluted EPS of $1.46. Gross product sales were $85,624 (thousands) offset by $21,557 (thousands) in discounts and allowances.
For the nine months ended September 30, 2025, revenue was $224,480 (thousands) and net income was $98,959 (thousands), aided by a $39,981 (thousands) release of cost share liability recognized in Q2. Cash, cash equivalents and short‑term investments were $137,200 (thousands) as of September 30, 2025. Customer concentration remained high, with McKesson accounting for 48% of Q3 net product sales. Shares outstanding were 18,151,344 as of October 30, 2025.
Rigel Pharmaceuticals, Inc. received joint Schedule 13G/A filings from Morgan Stanley and Morgan Stanley Capital Services LLC reporting passive ownership in the company's common stock. The combined report shows 116,406 shares beneficially owned by Morgan Stanley with
Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, was granted a performance-based employee stock option covering 7,394 shares of common stock with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The option was originally granted on January 29, 2025 with an expiration date of January 29, 2035. Because the grant was subject to a performance-based vesting condition, it became reportable only after the company determined the performance metric was satisfied on September 15, 2025, at which point the option fully vested. Following the determination, the reporting shows 7,394 shares underlying the option beneficially owned, held directly. The Form 4 was signed by an attorney-in-fact and filed on September 17, 2025.
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL) reported that a performance-based employee stock option covering 7,394 shares of common stock vested on September 15, 2025 after the required performance metric was determined to have been met. The option was originally granted on January 29, 2025 with an exercise price of $22.49 (the closing Nasdaq price on the grant date). The filing shows the option relates to 7,394 underlying shares and lists an expiration date of January 29, 2035. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Raymond Furey, on September 17, 2025.